The treatment dosage of SCT‐1015 was 10‐fold lower than another AMPK activator, metformin (250 mg·kg−1·five days per week−1·oral−1) with a similar tumor suppression tendency, indicating the strong potential in clinical therapeutic applications. Here, PRKAB1 is linked to neoplasm.